The growth of Viagra and its impact on the pharmaceutical landscape presents a complicated question for investors. While the first sales figures were impressive, the intellectual property has lapsed, leading to a flood of generic alternatives that are reducing profit. Moreover, the sector is facing issues related to population trends and evolving h